PreludeDx™ to Present DCISionRTÒ and Novel Resid

/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Related Keywords

San Antonio , Texas , United States , Australia , Perth , Western Australia , Chirags Shah , Dan Forche , Andrew Wade , Cory Dunn , Yvonne Zissiadis Jr , Instagram , Linkedin , Prnewswire Prelude Corporation Preludedx , National Cancer Institute , Prelude Corporation , American Society For Radiation Oncology , Taussig Cancer Institute , Facebook , University Of California San Francisco , Department Of Radiation Oncology , Henryb Gonzalez Convention Center , Residual Risk Subtype , Annual American Society , Radiation Oncology , Convention Center , Re Thinking Clinicopathologic Risk Assessment , Pooled Data , Validation Studies Comparing , Clinicopathologic Features , Breast Radiation Oncology , Cleveland Clinic , Will Be Presented , Prospective Registry , Clinical Utility , Biomarker Assay , Treatment Decisions , Breast Conserving , Radiation Oncologist , California San Francisco , Decision Score , Know Your Risk , Fjord Ventures , Investor Contact , Preludedx ,